Changeflow GovPing Healthcare & Life Sciences Effects of Berberine on Cardiometabolic Outcomes
Routine Notice Added Final

Effects of Berberine on Cardiometabolic Outcomes

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH registers a randomized, placebo-controlled clinical trial (NCT07541898) on Berberine, an alkaloid compound, as a dietary intervention for cardiometabolic outcomes. The trial will enroll participants diagnosed with Cardiometabolic Syndrome and randomly assign them to receive Berberine or placebo. Conditions studied include cardiovascular disease and type 2 diabetes mellitus. Results will be reported to ClinicalTrials.gov.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

ClinicalTrials.gov registered a new randomized, placebo-controlled trial (NCT07541898) investigating Berberine as a dietary intervention for cardiometabolic health. The study will enroll participants with Cardiometabolic Syndrome and randomize them to Berberine or placebo. No regulatory obligations or compliance requirements arise from this registration. Investigators conducting clinical trials involving Berberine or cardiometabolic interventions should register results on ClinicalTrials.gov per applicable federal requirements.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Effects of Berberine on Cardiometabolic Outcomes

N/A NCT07541898 Kind: NA Apr 21, 2026

Abstract

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Berberine may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

Conditions: Cardiometabolic Syndrome

Interventions: Berberine, Placebo

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 21st, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07541898

Who this affects

Applies to
Healthcare providers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial registration Drug research
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!